Tested in mice, curcumin suppresses the development of colon cancers and preneoplastic lesions in mice. Even though these studies show that curcumin is potentially chemo-productive during the beginning stages of cancer, it still does not explain the effectiveness of it during the progression stages. This is where we come in; we will analyze every step of the effects of curcumin during the premalignant stages and its progression to malignancy.
More testing showed that dietary curcumin of .2% reversed the effects of hypercholesterolemia. It lowered lipid peroxidase in rats with hypercholesterolemia. In human volunteers, an oral dose of 20mg of curcumin enhanced the contraction of the gall bladder and it was observed by ultrasound.
These studies were done in many different laboratories and have seen a variety of “experimental pathologies and endpoints in tissues, including immune cells, brain, lung, liver, kidney, gall bladder and blood, suggests that curcumin has substantial biological effects outside the GI tract despite its relatively poor bioavailability.” (Curcimin: From ancient medicine to current clinical trials). There seems to be many environmental factors that could potentially change the effect of curcumin, but that remains unknown. More testing needs to be done on these possible factors, but, with the funds, we are able to eliminate or minimize the problems …show more content…
Sodium acetate, Prominence® UFLC (Shimadzu Corp.) for colon biopsies, methanol, and water.
Participants: We need to gather men and women above the age of 45 who are current smokers and have a history of smoking three packs per day for at least 2 years, and a greater than or equal to 8 rectal aberrant crypt foci (ACF), which is in the lining of the colon and rectum, observed by chromo endoscopy. Written consent must be taken from each person in this study, which will be approved by the Institutional Review boards.
Study plan: The trials will consist of cancer prevention given a dose of oral curcumin once a day for 30 days to decrease the concentrations of enzymes within aberrant crypt foci and in associated normal mucosa. There will be secondary endpoints in total aberrant crypt foci number and an estimate of proliferation in normal mucosa using a specific proliferation marker. The trial will be done in two stages. First is an oral dose 2 grams of curcumin once a day. We will then conduct a formal toxicity review and determine the acceptable toxicity levels after the first stage has been completed. Once it is established, we are able to move on to stage 2, which is an oral dose of 4 grams once per day daily. The ranges will be established by the Food and Drug Administration and National Cancer Institute Division of Cancer Prevention before conducting this